SNIPPET: Endotrophin, a collagen VI-derived matrikine, is emerging as a critical biomarker linking obesity, heart failure, and cardiometabolic disease. A novel full-length endotrophin immunoassay now enables more precise measurement in heart failure with preserved ejection fraction (HFpEF), with elevated levels independently associated with cardiovascular and all-cause mortality across clinical cohorts.

Endotrophin: The Collagen Fragment Connecting Obesity, Heart Failure, and Cardiometabolic Risk

Endotrophin is a biologically active peptide cleaved from the C-terminus of the alpha-3 chain of type VI collagen (COL6A3), functioning as both a signaling molecule and a circulating biomarker for fibroinflammatory disease. It matters because it sits at the intersection of adipose tissue dysfunction, cardiac fibrosis, and metabolic deterioration — three processes that collectively drive the leading causes of death worldwide. A proteogenomic analysis published in Nature Genetics by Yoshiji et al. identified endotrophin as a causal mediator of the effect of obesity on coronary artery disease risk, with body mass index strongly increasing COL6A3-derived endotrophin levels^[3]. Multiple research groups, from Nordic Bioscience to academic cardiology centers, are now converging on endotrophin as a measurable, modifiable target in what the American Heart Association has termed cardiovascular-kidney-metabolic (CKM) syndrome.

THE PROTOHUMAN PERSPECTIVE#

Here's why I think this matters beyond the cardiology journals.

We spend enormous energy optimizing single biomarkers — glucose, LDL, testosterone — while ignoring the extracellular matrix (ECM), which is literally the structural scaffold your organs depend on. Endotrophin is a signal that your ECM is being actively remodeled, and not in a good way. It's a fibrosis alarm.

For anyone tracking body composition, metabolic health, or cardiac function, endotrophin represents something we've lacked: a circulating marker that bridges adipose tissue pathology to end-organ damage. The fact that body fat reduction can lower endotrophin levels makes it one of the few biomarkers where the intervention is straightforward — lose fat. Not "optimize your stack." Not "cycle this peptide." Lose fat. Which is annoying, actually, because it's the advice nobody wants and everybody needs.

The development of a full-length assay means we may soon be able to track this in clinical practice, moving endotrophin from research curiosity to actionable data point.

THE SCIENCE#

What Endotrophin Actually Is — and Why the Assay Matters#

Endotrophin is a matrikine — a bioactive fragment released during ECM turnover. Specifically, it's cleaved from COL6A3, one of the three chains forming type VI collagen, which is abundant in adipose tissue, cardiac interstitium, and skeletal muscle connective tissue^[2]. Until now, circulating endotrophin has been quantified using the PRO-C6 assay, which detects various proteolytic fragments of the COL6A3 C-terminus, not exclusively full-length endotrophin^[1].

The problem with PRO-C6 — and I've found this consistently frustrating when reviewing ECM biomarker literature — is that it measures a mixed bag of fragments. You're not sure if you're detecting the biologically active endotrophin molecule or inert degradation products. The novel immunoassay described in Scientific Reports (March 2026) was designed to target full-length endotrophin specifically, which should improve biological specificity considerably^[1].

In two independent HFpEF cohorts, increased circulating full-length endotrophin was associated with both cardiovascular mortality and all-cause mortality. After adjusting for relevant confounders (age, renal function, NT-proBNP), endotrophin remained independently prognostic in cohort 1^[1]. The fact that it lost independence in cohort 2 after adjustment is worth noting — it doesn't invalidate the finding, but it tells us endotrophin's prognostic signal may be partially captured by existing markers in some populations.

The Obesity–Endotrophin–Coronary Artery Disease Axis#

This is where the data gets genuinely interesting.

Yoshiji et al. used two-step proteome-wide Mendelian randomization — a method that leverages genetic variants as instruments to estimate causal effects — and identified COL6A3 as one of five proteins mediating the effect of obesity on coronary artery disease^[3]. Endotrophin, the carboxyl terminus product of COL6A3, drove this effect. BMI strongly increased COL6A3 levels, which in turn increased CAD risk. The team integrated colocalization analysis, epigenomics, and single-cell RNA sequencing to confirm that COL6A3 was highly expressed in disease-relevant tissues, including adipose and vascular cells.

The critical translational finding: body fat reduction could reduce plasma levels of COL6A3-derived endotrophin^[3]. This makes endotrophin a tractable target — you don't need a novel drug. You need fat loss. The Mendelian randomization design adds causal credibility that observational studies alone cannot provide, though I'd want to see interventional trials confirming the magnitude of reduction before prescribing specific fat-loss targets.

Ethnic Variation and Metabolic Context#

Let me push back on the assumption that endotrophin behaves uniformly across populations, because the data says otherwise.

A study published in BMC Cardiovascular Disorders examined serum endotrophin in young South Asian versus White women at one year postpartum^[4]. Despite no significant difference in absolute endotrophin concentrations between the groups (median 19.3 ng/ml vs 17.3 ng/ml, p = 0.37), the correlations told a completely different story. Endotrophin was positively correlated with systolic blood pressure in South Asian women (r = 0.43, p = 0.006) but showed zero correlation in White women (r = −0.02, p = 0.89)^[4]. The same divergence appeared with fasting glucose.

This is a small study — 40 per group — so I'm cautious about over-interpreting. But it raises a question that rarely gets asked in biomarker research: does this marker mean different things in different populations? If endotrophin's vascular effects are ethnicity-dependent, a universal reference range would be clinically misleading.

Endotrophin and Insulin Resistance#

Li et al. demonstrated that newly diagnosed type 2 diabetes patients had higher serum endotrophin levels compared to healthy controls, and that two weeks of intensive insulin pump therapy significantly reduced those levels^[5]. Changes in endotrophin (δ-ETP) were independently associated with changes in insulin resistance as measured by HOMA2-IR (δ-HOMA2-IR)^[5].

The sample was small (n = 40 per group), and the mechanism isn't fully clear — does insulin itself suppress endotrophin production, or does glycemic control reduce adipose tissue inflammation, which then reduces COL6A3 turnover? The honest answer: we don't know yet.

COMPARISON TABLE#

THE PROTOCOL#

If you're interested in monitoring and modifying your endotrophin-related risk based on current evidence, here's what the data supports — with appropriate caveats.

Step 1: Assess your baseline cardiometabolic risk profile. Get standard bloodwork: fasting glucose, HbA1c, fasting insulin, lipid panel, hs-CRP, NT-proBNP (if cardiac symptoms exist), and eGFR. These contextualize any future endotrophin measurement. Without this baseline, an endotrophin level is uninterpretable.

Step 2: Request PRO-C6 testing if available. The full-length endotrophin assay isn't commercially available yet. PRO-C6, while imperfect, is the current research-grade option for quantifying COL6A3 C-terminal fragments. Ask your physician or a research-oriented lab about availability. This is not standard of care — frame it as a research interest.

Step 3: Prioritize body fat reduction as the primary intervention. Yoshiji et al.'s Mendelian randomization data indicates that reducing body fat lowers circulating COL6A3-derived endotrophin^[3]. Target a sustained caloric deficit through whichever dietary approach you can maintain. Evidence does not yet specify an optimal rate or magnitude of fat loss for endotrophin reduction specifically.

Step 4: Address insulin resistance directly. Based on Li et al., improving insulin sensitivity appears to lower endotrophin levels^[5]. Practical approaches: resistance training (3–4 sessions/week), time-restricted eating if tolerated, and ensuring adequate sleep (7–9 hours) to support glucose regulation and autophagy pathways.

Step 5: Monitor inflammatory markers longitudinally. Track hs-CRP and fasting insulin every 3–6 months as proxy indicators of the fibroinflammatory state that endotrophin reflects. A declining hs-CRP alongside body fat reduction suggests you're moving in the right direction.

Step 6: Reassess when the full-length assay becomes clinically available. The novel immunoassay described by the Scientific Reports team will likely be commercialized within the next few years. When it is, a direct full-length endotrophin measurement will provide more specific data than PRO-C6.

VERDICT#

Score: 7/10. The convergence of Mendelian randomization data, clinical cohort studies, and a new precision assay makes endotrophin one of the more credible emerging cardiometabolic biomarkers I've reviewed recently. The causal link from obesity through COL6A3 to coronary artery disease is well-supported genetically. The catch, though — clinical utility is still pre-commercial, the full-length assay needs validation in larger, more diverse populations, and the ethnic variation data suggests we're early in understanding who this biomarker actually serves best. The strongest evidence points toward fat loss as the lever, which is both reassuringly simple and frustratingly nonspecific. I'd want two more things before scoring higher: a large multi-ethnic prospective study and evidence that lowering endotrophin actually changes outcomes, not just that it predicts them.#